N1 Life
PrivateLast Round
Series A
Apr 17, 2024
Total Funding Raised
$10M
Company Overview
N1 Life is a biotechnology company that develops innovative peptide-based drug delivery platforms and peptide drug conjugates to improve the targeted efficacy of active ingredients in skincare and therapeutic applications.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Advanced Materials, Fashion & Beauty, Medical AI
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share, Data as a Service
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
N1 Life Comps
Public and private peers based on sector, stage, and business model.
N1 Life Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Apr 17, 2024 | ||||
| Pre Seed | Apr 17, 2023 |
N1 Life Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Legend Capital | Pre Seed |
| FreesFund | Pre Seed |
| California Life Sciences | Pre Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- May 11, 2026
Open roles increased from 0 to 6, representing 67% of headcount.
N1 Life Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about N1 Life's valuation, stock price, and market status.
